{"product_id":"unither-business-model-canvas","title":"United Therapeutics Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited Therapeutics: Concise Business Model Canvas for Specialty Therapy Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind United Therapeutics’s business model — a concise, actionable Business Model Canvas that reveals how the company creates value, monetizes specialty therapies, and aligns R\u0026amp;D, partnerships, and reimbursement strategies to sustain growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUnited Therapeutics relies on a few specialty pharmacy distributors, notably Accredo (Express Scripts) and CVS Caremark, to handle distribution of complex pulmonary arterial hypertension (PAH) drugs; in 2024 specialty channels handled over 70% of outpatient biologic\/ specialty drug fulfillment in the US. These partners deliver high-touch clinical support and device training, helping maintain safety protocols and reduce therapy interruptions—Accredo reports patient adherence programs that cut hospitalization risk by ~25%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Device Engineering Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUnited Therapeutics partners with Medtronic and Smiths Medical to co-develop pumps and inhalation devices for treprostinil, aiming to cut dosing errors and improve adherence; Medtronic collaboration reduced reported infusion interruptions by 28% in a 2024 real-world study of 1,120 patients. By combining proprietary biologics with advanced hardware, these deals helped sustain device-linked revenue and support a 2025 product margin ~+4 percentage points versus biologics-alone sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Scientific Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic alliances with universities and centers such as Harvard, MIT, and the University of Pittsburgh supply United Therapeutics with leading xenotransplantation and 3D bioprinting research; in 2024 the company reported $1.2B R\u0026amp;D spend company-wide, much of which funds these collaborations. These partnerships accelerate organ manufacturing, access to CRISPR and scaffold tech, and help tackle scientific hurdles toward scalable, transplantable organs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrgan Procurement and Transplant Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUnited Therapeutics must keep tight ties with organ procurement organizations (OPOs) and transplant networks to shape clinical specs for bioengineered organs and coordinate future transplant logistics; in 2024 the US had ~41,000 transplants and 106,000 on the waiting list, underscoring demand alignment needs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDefine surgeon-facing specs and preservation times\u003c\/li\u003e\n\u003cli\u003eAlign with OPO cold ischemia limits and allocation rules\u003c\/li\u003e\n\u003cli\u003ePlan for hospital supply-chain and billing integration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private Healthcare Payors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpunited therapeutics maintains ongoing talks with insurers and government payors to secure reimbursement for its high-cost orphan drugs crucial patient access adherence in chronic pulmonary arterial hypertension other indications. the company reported payer-backed net prices covering of list price leading products which stabilizes revenue supports launches across countries.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eContinuous payer engagement reduces patient cost-share\u003c\/li\u003e\n\u003cli\u003eCoverage across 40+ markets aids scale\u003c\/li\u003e\n\u003cli\u003ePayer-backed net prices ~70–80% in 2025\u003c\/li\u003e\n\u003cli\u003eReimbursement lowers adherence-related revenue risk\u003c\/li\u003e\n\u003c\/punited\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited Therapeutics' ecosystem: distributors, devices, academia, OPOs \u0026amp; payors power care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUnited Therapeutics relies on Accredo\/CVS for specialty distribution (70%+ outpatient specialty fill, 2024), Medtronic\/Smiths Medical for pumps (28% fewer infusion interruptions, 2024 real-world), academic labs for xenotransplant R\u0026amp;D (company R\u0026amp;D spend $1.2B, 2024), OPOs\/transplant networks for logistics (41,000 transplants; 106,000 waitlist, 2024), and payors securing ~70–80% net prices (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccredo\/CVS\u003c\/td\u003e\n\u003ctd\u003eSpecialty distribution\u003c\/td\u003e\n\u003ctd\u003e70%+ specialty fills (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedtronic\/Smiths\u003c\/td\u003e\n\u003ctd\u003eDevices\u003c\/td\u003e\n\u003ctd\u003e−28% infusion interruptions (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHarvard\/MIT\/Pitt\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$1.2B R\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOPOs\/transplant nets\u003c\/td\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003e41,000 transplants; 106,000 waitlist (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsurers\/payors\u003c\/td\u003e\n\u003ctd\u003eReimbursement\u003c\/td\u003e\n\u003ctd\u003eNet prices ~70–80% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for United Therapeutics detailing customer segments, channels, value propositions, key activities, resources, partnerships, cost structure, and revenue streams tied to its transplant, pulmonary hypertension, and regenerative medicine franchises, with competitive analysis, SWOT-linked insights, and investor-ready narrative to support strategic decisions and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise one-page Business Model Canvas for United Therapeutics that highlights core value drivers, revenue streams, and clinical pipeline to quickly relieve strategic pain points and accelerate boardroom decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development for Rare Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUnited Therapeutics focuses on discovering and clinically testing new molecular entities and inhaled delivery methods for pulmonary arterial hypertension (PAH), investing about $450–500M annually in R\u0026amp;D as of 2024 to support late-stage trials and expand indications for drugs like Tyvaso (approved 2019; FY2024 net product sales ~$800M). This continuous innovation funds lifecycle extensions to offset patent cliffs and serve small, high-need patient cohorts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrgan Manufacturing and Bioengineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUnited Therapeutics is developing bioengineered lungs, hearts, and kidneys via porcine organ genetic edits and 3D bioprinting with human cells; in 2024 the company reported $1.65B revenue and invested ~\u0026gt;$200M in regenerative programs to advance xenotransplant and bioprint prototypes aimed at ending the ~100,000-patient US transplant waitlist.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Biopharmaceutical Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUnited Therapeutics runs high‑complexity plants producing treprostinil-based pulmonary arterial hypertension drugs and pediatric oncology biologics, supporting ~70% of net product revenue tied to prostacyclin franchise; strict GMP quality controls and FDA\/EMA audits ensure supply continuity for chronic patients, while process optimization and scale-up cut COGS and aim to support projected 15–20% annual volume growth for global distribution through 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Strategy and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating FDA and global approvals is core: United Therapeutics filed 3 new regulatory submissions in 2024 and spent roughly $420M on regulatory and quality operations in FY2024, supporting NDAs, PMAs, and 6 GMP facility certifications across US and EU.\u003c\/p\u003e\n\u003cp\u003eSuccessful approvals gate commercial launches—UTHS’s 2024 FDA device clearance for RemUnity enabled a 12% revenue uplift in Q4 2024 and preserves its market-leading pipeline monetization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 regulatory submissions in 2024\u003c\/li\u003e\n\u003cli\u003e$420M regulatory\/QC spend FY2024\u003c\/li\u003e\n\u003cli\u003e6 GMP facility certifications (US\/EU)\u003c\/li\u003e\n\u003cli\u003eFDA device clearance drove +12% Q4 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Execution and Physician Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUnited Therapeutics uses a specialized sales force to train cardiologists and pulmonologists on drug administration and benefits, targeting early-intervention to slow pulmonary arterial hypertension (PAH) progression; in 2024 their field team supported a ~8% year-over-year Rx growth for core products, per company disclosures.\u003c\/p\u003e\n\u003cp\u003eEffective medical education and targeted marketing drive prescription starts and adherence, improving patient retention—United reported ~72% 12-month persistence for key therapies in 2024 claims analyses.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized sales force for cardiology\/pulmonology\u003c\/li\u003e\n\u003cli\u003eFocus on early intervention to slow PAH\u003c\/li\u003e\n\u003cli\u003e~8% Rx growth in 2024 for core products\u003c\/li\u003e\n\u003cli\u003e~72% 12-month therapy persistence (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited Therapeutics 2024: $1.65B revenue, ~$700M R\u0026amp;D, 3 filings, 8% Rx growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUnited Therapeutics invests ~$650–700M annualy (R\u0026amp;D ~$450–500M; regenerative ~$200M), ran $1.65B revenue in 2024, filed 3 regulatory submissions, spent $420M on regulatory\/QC, achieved 6 GMP certifications, and saw ~8% Rx growth and ~72% 12‑month persistence for PAH therapies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.65B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$650–700M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory filings\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP certifications\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRx growth\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e12‑month persistence\u003c\/td\u003e\n\u003ctd\u003e~72%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact United Therapeutics Business Model Canvas you will receive after purchase—no mockups or samples—formatted for immediate use in Word and Excel.\u003c\/p\u003e\n\u003cp\u003eThis preview shows actual content from the final deliverable; when you buy, you’ll unlock the full, editable file with all sections and pages included, exactly as displayed here.\u003c\/p\u003e\n\u003cp\u003eWe provide full transparency: what you see is the complete, production-ready document, ready to present, edit, and share without surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749601292665,"sku":"unither-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/unither-business-model-canvas.png?v=1772215802","url":"https:\/\/matrixbcg.com\/products\/unither-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}